Imaging AI in Colorado

Ultrasound AI is a healthcare technology company founded in 2019 that develops AI-powered software tools for maternal and neonatal healthcare. The company's flagship product, Delivery Date AI™, uses artificial intelligence trained on over 8 million ultrasound images to accurately predict delivery dates in singleton pregnancies (14–36 weeks gestation) where a reliable estimated delivery date is unavailable. Delivery Date AI™ received FDA De Novo authorization in 2026 and is currently approved for clinical use in the United States, Brazil, and Chile. The company also developed Preterm AI™, designed to identify risks of preterm birth and enable proactive clinical interventions. Ultrasound AI holds six issued patents across three countries and positions its solutions as decision-support tools that augment clinician judgment in obstetric care, addressing the critical clinical need for accurate pregnancy dating to improve maternal and neonatal outcomes.

Hangzhou Diagens Biotech is a Chinese manufacturer of intelligent medical devices and software platforms specializing in cytogenetics, medical imaging AI, and diagnostic solutions. The company produces a comprehensive suite of automated cytogenetics systems, including the AI AutoVision chromosome karyotype assisted diagnosis system, AutoVision chromosome analysis systems, MetaSight automatic cell microscopic image scanning, and the KayoFlow workflow (comprising automatic cell harvesters and integrated slide preparation/staining systems). Diagens also manufactures cytogenetics laboratory reagents and consumables. Beyond hardware, the company develops and offers iMedImage foundation models and the iMed MaaS medical imaging AI platform for localized computation, training, and inference. Clinical solutions include AI-driven genetics health solutions (reproductive genetics), radiological health solutions, and hematology solutions. The company provides model services and research solutions built on its iMedImage platform. Diagens maintains headquarters in Hangzhou, Zhejiang Province, China, and operates under Chinese regulatory frameworks (Internet Drug Information Service Qualification Certificate). The product portfolio targets clinical laboratories, genetics testing facilities, and healthcare institutions requiring automated cytogenetic analysis and AI-enhanced diagnostic capabilities.

Aclarion, Inc. is a healthcare technology company specializing in noninvasive diagnostic software for chronic low back and neck pain management. The company develops the NOCISCAN platform, a SaaS solution that leverages magnetic resonance spectroscopy (MRS) to analyze pain biomarkers in lumbar discs and distinguish between painful and nonpainful vertebral segments. NOCISCAN complements conventional lumbar MRI imaging by providing objective, patient-specific pain biomarker data without requiring invasive provocative discography. The platform generates individualized NOCI+/NOCI- scores for each disc, enabling clinicians to personalize treatment and surgical planning. NOCISCAN integrates with existing high-field MRI systems and includes components such as the MRS Exam Protocol, AMBRA Healthcare integration, and NOCIWEB data transfer capabilities. The solution supports improved surgical outcomes by helping physicians identify the true source of discogenic pain and optimize candidate selection for interventional procedures including fusion and disc replacement.

Enlitic is a healthcare AI software company specializing in medical imaging data solutions and workflow optimization. The company develops AI-driven platforms for standardizing, anonymizing, and migrating medical imaging data (DICOM) within healthcare organizations. Core products include ENDEX™ (DICOM data standardization and quality enhancement), ENCOG™ (PHI data anonymization and compliance), and Migratek® (AI-enabled data migration for healthcare M&A and system transitions, developed in partnership with Laitek). Enlitic's solutions target radiologists, IT professionals, hospital executives, and clinical researchers. The platform streamlines imaging workflows, reduces data errors, enhances hanging protocols, and enables secure data preparation for clinical research and analytics. The company positions itself as an enabler of insights from medical imaging archives, supporting operational efficiency, regulatory compliance, and data-driven clinical decision-making. Services address healthcare provider infrastructure optimization, imaging data quality, workflow automation, and secure data collaboration across systems.

MuscleSound is a Colorado-based digital health company that develops point-of-care ultrasound analytics software to assess malnutrition, sarcopenia, frailty, and cachexia. The proprietary platform automates analysis of ultrasound images to quantify muscle health and nutritional status at the bedside, providing clinicians with objective diagnostic data. MuscleSound's cloud-based software integrates with existing clinical ultrasound technology and delivers immediate, actionable insights across surgical, critical care, oncology, cardiology, physical medicine & rehabilitation, and pediatric settings. The non-invasive assessment tool measures muscle size, quality, and energy status—positioning muscle health as a vital sign for patient care optimization. Developed in partnership with Duke University Medical Center, University of Colorado School of Medicine, and other leading institutions, MuscleSound enables higher diagnostic accuracy, improved documentation, potential cost savings, and reimbursement optimization by addressing the hidden epidemic of hospital-associated malnutrition.

Rapid AI develops deep clinical artificial intelligence software for medical imaging analysis, specializing in neurovascular, cardiac & vascular, and radiology applications. The company's Rapid Enterprise™ Platform delivers FDA-cleared clinical decision support modules that enhance diagnostic confidence and streamline workflows across 2,500+ hospitals in 100+ countries. Core offerings include AI-driven triage, localization, quantification, characterization, and 3D visualization capabilities for stroke (hemorrhagic and ischemic), aneurysm, pulmonary embolism, and general radiology cases. The mobile app enables real-time alerts, case collaboration, DICOM viewer integration, EMR connectivity, and procedural workflow initiation. Rapid AI products include Lumina 3D (advanced 3D rendering and analysis, named to TIME's Best Inventions 2025), Navigator Pro (radiology workflow prioritization), and Rapid Insights (custom analytics). The company has received 30 FDA-cleared modules and maintains extensive clinical validation: 700+ peer-reviewed publications, 25+ clinical trials, 11 NEJM publications, and 17.5 mean impact factor. Processing 20,000+ daily scans, Rapid AI serves stroke centers, trauma departments, cardiac services, and life sciences organizations conducting clinical trials. The platform supports interoperability with third-party healthcare systems and EMRs, enabling cross-disciplinary deployment of AI decision support.

Biodesix is a CLIA-certified and CAP-accredited life sciences diagnostics company specializing in AI-driven, blood-based diagnostic tests for lung cancer and related respiratory diseases. Founded in 2005 and publicly traded since 2020, the company combines multi-omic approaches—including genomics, proteomics, and advanced mass spectrometry—with proprietary artificial intelligence algorithms to deliver personalized diagnostic solutions. Flagship offerings include the Nodify Lung Nodule Risk Assessment and IQLung Strategy Tests, which guide clinical decision-making for lung nodule management and non-small cell lung cancer treatment selection. Beyond clinical diagnostics, Biodesix operates a robust biopharma services division providing translational research, biomarker discovery, companion diagnostic development, and clinical trial support to leading biopharmaceutical and research institutions. The company's liquid biopsy technology platform enables non-invasive risk stratification and prognostic assessment, addressing a critical clinical need in early cancer detection and precision oncology.

Cleerly is an AI-driven software platform that enhances coronary CT angiography (CCTA) analysis for comprehensive coronary artery disease (CAD) assessment. The platform delivers quantitative, clinically actionable insights through automated 3D modeling of coronary arteries, plaque detection and characterization, stenosis measurement, and ischemia likelihood determination. Cleerly's core offerings include: AI-powered CAD analysis with 3D arterial reconstruction; plaque phenotyping (soft, fibrous, calcified); stenosis quantification in 2D and 3D; ischemia assessment via the proprietary Cleerly ISCHEMIA algorithm; and serial scan comparison (Cleerly COMPARE) for longitudinal CAD tracking. The platform integrates with PowerScribe for streamlined reporting workflows. Clinical validation includes the prospective CREDENCE trial (868 invasive FFR measurements) demonstrating superior diagnostic accuracy versus FFRCT and stress testing, and post-hoc PACIFIC study analysis showing Cleerly ISCHEMIA as the only non-invasive test prognostic of major adverse cardiac events. The solution targets cardiologists, interventional radiologists, and cardiac imaging centers seeking to reduce unnecessary invasive procedures and improve diagnostic confidence. The company supports commercial insurance reimbursement and provides web-based access to the platform. Designed for hospital and outpatient cardiac imaging workflows.